A quality-adjusted survival analysis (Q-TWiST) of rituximab plus CVP vs CVP alone in first-line treatment of advanced follicular non-Hodgkin's lymphoma

R Marcus, R Aultman, F Jost
2009 British Journal of Cancer  
doi:10.1038/sj.bjc.6605443 pmid:19920818 pmcid:PMC2813752 fatcat:injbg3kdlzaezmrvqvw5ph7g7a